azetidyl-2-carboxylic acid has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, K; Jinnouchi, H; Jinnouchi, T; Kim-Mitsuyama, S; Matsui, K; Ogawa, H | 1 |
| Inoue, H; Nakamura, K; Yamagishi, S | 1 |
1 trial(s) available for azetidyl-2-carboxylic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Japan; Male; Prospective Studies; Single-Blind Method; Survival Analysis; Tetrazoles; Treatment Outcome | 2012 |
1 other study(ies) available for azetidyl-2-carboxylic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Topics: Antihypertensive Agents; Antioxidants; Arteriosclerosis; Azetidinecarboxylic Acid; Biomarkers; Calcium; Cardiovascular Diseases; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus; Dihydropyridines; Endothelium, Vascular; Humans; Hypertension; Insulin Resistance; Interleukin-8; Models, Biological; Reactive Oxygen Species; Transcription Factor AP-1; Tumor Necrosis Factor-alpha; Umbilical Veins | 2005 |